T irofiban, a GP (glycoprotein)-IIb/IIIa inhibitor, is commonly used in China to prevent reocclusion after endovascular thrombectomy (EVT). However, there is limited evidence about the safety and effectiveness of tirofiban in the setting of EVT for ischemic stroke patients. Two studies reported conflicting findings, with a German study 1 showing tirofiban-increased risk of fatal intracranial hemorrhage (ICH), and a Chinese study 2 reporting no increased risk of symptomatic ICH (sICH) or fatal ICH with tirofiban treatment. The 2 studies used different doses of tirofiban, which may have caused the conflicting findings. In current study, we aimed to further study the relationship of tirofiban and ICH. Moreover, we aimed to observe whether the relationship was dose-dependent.
Methods
The authors declare that all supporting data are available within the article and its online-only Data Supplement.
Study Design
This was a prospective study, designed to provide tirofiban to all EVT patients for 2 continuous years. However, tirofiban was only used for 1 year and stopped for safety concern (as the investigators noted high rates of ICH); the observation continued for another year where no tirofiban was used. Thus, 2 groups of patients were included, the tirofiban group and non-tirofiban group. The 2 groups were then compared in terms of cerebral hemorrhagic rates and clinical outcomes. Thus, the study was a nonrandomized treatment comparison study.
Patients
The study recruited patients at Ningbo First Hospital and Hangzhou First Hospital, China. The study was approved by the institutional ethics committee, and informed consent was obtained for all patients. Patients were included in this study if eligible for EVT according to the guidelines recommended by the Chinese Society of Neurology. The eligibility criteria and EVT procedure were summarized in the online-only Data Supplement. All patients received standard postthrombectomy care in accredited stroke units. The 2 centers are in the same province and have similar stroke care protocols.
Tirofiban
For patients who had EVT on 2016, the procedure was followed by an intra-arterial bolus of tirofiban (Tirofiban Hydrochloride and Sodium Chloride Injection, Grand Pharmaceutical Co Ltd, China). Tirofiban was injected at a rate of 1 mL/min (50 μg/mL). The maximum dose of tirofiban was 10 μg/kg, and the following 2 doses were given to patients at the discretion of the interventionists, considering individual patient risk of bleeding: 1/3 of the maximum dose (3.4 μg/ kg), 2/3 of the maximum dose (6.7 μg/kg), and full dose (10 μg/kg).
Hemorrhagic Outcomes
sICH was the primary outcome of this study, defined by the ECASS III (European Cooperative Acute Stroke Study III) criteria. 3 Other hemorrhagic outcomes included (1) any ICH, (2) PH2 (parenchymal hematoma type 2), and (3) fatal ICH. In addition, clinical outcomes © 2018 American Heart Association, Inc.
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Statistical Analysis
For patient characteristics and outcomes, differences between groups were estimated by Mann-Whitney test for continuous data and χ 2 test for binary data. All statistical analysis was done using STATA 13.0 (Stata Corp, College Station, TX), with CI set at 95% and significant level set at 0.05.
To assess the predictive power of tirofiban on hemorrhagic outcomes, 3 types of simple logistic model were used in this study: (1) the first model treated tirofiban as a binary predictor, comparing the non-tirofiban group and tirofiban group; (2) the second model treated tirofiban as a categorical predictor: tirofiban dose of 0, 3.3, 6.7, and 10 μg/kg; (3) the third model treated tirofiban as a continuous variable, ranging from dose of 0 to 10 μg/kg. Afterwards, multivariate logistic regression models were performed to adjust for confounders.
Results

Patients
In this study, 218 patients were included, with 94 receiving tirofiban and 124 did not. Patient characteristics and EVT components were summarized in Table I 
Tirofiban and Hemorrhagic Outcomes
The tirofiban group had significantly higher rate of sICH (14.6% versus 5.7%; P=0.027; Table 1 ). Tirofiban treatment also caused a significant increase in rate of any ICH (38.3% versus 9.7%; P<0.001), PH2 (8.5% versus 2.4%; P=0.042), and fatal ICH (8.8% versus 1.6%; P=0.014). Tirofiban-treated patients had an increased odds of sICH by 2.9-fold (95% CI, 1.1-7.5). The odds of any ICH increased by 5.8-fold (95% CI, 2.8-11.9), odds of PH2 increased by 3.8-fold (95% CI, 1.0-14.6), and odds of fatal ICH increased by 5.9-fold (95% CI, 1.2-28.4). After adjusting for stroke type (anterior circulation versus posterior circulation stroke), atrial fibrillation history, intravenous tPA (tissue-type plasminogen activator) treatment, stent implanting, and angioplasty, the tirofiban group still had significantly higher odds of having sICH (odds ratio=2. Table II in the online-only Data Supplement.
The tirofiban group showed a tendency towards increasing rate of in-hospital mortality (12.2% versus 5.0%), although the tendency was not statistically significant (P=0.055). Statistical analysis also showed no significant difference between the 2 groups in 3-month good outcome (modified Rankin Scale score of 0-1, 37% versus 42.6%; P=0.449), 3-month poor outcome (modified Rankin Scale score of 5-6, 39.5% versus 35.6%; P=0.592), or 3-month mortality rate (modified Rankin Scale score of 6, 29.6% versus 21.8%; P=0.226).
Tirofiban Dose and Hemorrhagic Outcomes
Of the 218 patients, 124 had no tirofiban, 19 received 1/3 dose of tirofiban, 57 received 2/3 dose, and 18 received full dose. Figure I in the online-only Data Supplement). Table 3 summarized hemorrhagic outcomes when the 4 tirofiban doses were as treated categorical variables. For sICH and fatal ICH, compared with patients receiving no tirofiban treatment (dose=0), patients treated with 1/3 dose did not show a significant increase of rate (P=0.988 and 0.329, respectively); the sICH and fatal ICH rate were significantly higher when patients treated with 2/3 dose (P=0.046 and 0.032, respectively) or full dose of tirofiban (P=0.023 and 0.050, respectively).
Discussion
This study suggests that the GP-IIb/IIIa inhibitor tirofiban increases ICH risk when combined with EVT treatment for acute ischemic stroke. Patients receiving tirofiban showed an increased risk of sICH by almost 3-fold. Tirofiban was also found to increase the risk of fatal ICH. The novel finding of this study is the dose-dependent effect of tirofiban on ICH. In previous studies of stroke patients, 1,2 single (but differing across study) doses of tirofiban have been delivered. This study directly compared different doses of tirofiban in acute stroke patients, although not in a randomized fashion. Currently, a bolus of 10 μg/kg is being mostly used in EVT patients, based on studies of myocardial infarction patients. 4 The current study indicates the dose of 10 μg/kg is not safe, causing symptomatic or even fatal bleeding. A lower dose of tirofiban (3.3 μg/kg) might be safe but more data are needed to assess whether this tirofiban actually improves reocclusion rates or clinical outcomes after EVT.
There are some limitations of this study. First, this was not a randomized study. There was a slight excess of posterior circulation stroke in the tirofiban group, and an increase in atrial fibrillation in the non-tirofiban group. These differences weaken the interpretation of the study results. However, the differences in baseline characteristics between the 2 groups were adjusted for in multivariable regression (Table II in the online-only Data Supplement). It is also unclear to us how these differences might relate to increased risk of ICH with tirofiban. Second, Tirofiban treatment did not correlate with the success of endovascular recanalization. The study does not indicate whether successful recanalization increases the risk of ICH with tirofiban.
In conclusion, findings of this study do not support the administration of tirofiban at the dose of 10 μg/kg for ischemic stroke patients undergoing EVT. 
